Clinical Laserthermia Systems AB (publ)

DB:LS60 Stock Report

Market Cap: €5.3m

Clinical Laserthermia Systems Valuation

Is LS60 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LS60 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LS60's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LS60's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LS60?

Key metric: As LS60 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LS60. This is calculated by dividing LS60's market cap by their current revenue.
What is LS60's PS Ratio?
PS Ratio3.3x
SalesSEK 18.63m
Market CapSEK 60.74m

Price to Sales Ratio vs Peers

How does LS60's PS Ratio compare to its peers?

The above table shows the PS ratio for LS60 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
AUG Audientes
12.6xn/a€6.9m
GME Geratherm Medical
1.6x1.9%€28.5m
AAQ1 aap Implantate
1.9xn/a€22.2m
PUS PULSION Medical Systems
3.7xn/a€133.6m
LS60 Clinical Laserthermia Systems
3.3x51.9%€60.7m

Price-To-Sales vs Peers: LS60 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the peer average (2.4x).


Price to Sales Ratio vs Industry

How does LS60's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$836.45m
PHH2 Paul Hartmann
0.3xn/aUS$787.19m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
LS60 3.3xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LS60 is good value based on its Price-To-Sales Ratio (3.3x) compared to the European Medical Equipment industry average (3.5x).


Price to Sales Ratio vs Fair Ratio

What is LS60's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LS60 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio0.1x

Price-To-Sales vs Fair Ratio: LS60 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies